CRBU (Caribou Biosciences) Moat Score: 5/10 (As of Jul. 11, 2026)


CRBU Caribou Biosciences Inc CRBU
64 GF Score
Price $1.93
GF Value $1.68
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Moat Score?

Caribou Biosciences CRBU -0.77% 64 Moat Score is 5 as of Jul. 11, 2026. GuruFocus rates CRBU with a GF Score™ of 64/100 and a GF Value™ of $1.68 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,395 Biotechnology companies, Caribou Biosciences ranks better than 96.7% on this metric.

Caribou Biosciences has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Caribou Biosciences has Narrow Moat: Caribou Biosciences has valuable intellectual property in CRISPR technology and strong R&D capabilities. However, the rapidly evolving biotech industry and competition from larger firms limit its moat to a solid narrow level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Caribou Biosciences might have Narrow Moat - Solid narrow moat.

Caribou Biosciences  (NAS:CRBU) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Caribou Biosciences Moat Score Related Terms

CRBU vs YDES, PRQR, CRBP: Moat Score Comparison

For the Biotechnology subindustry, Caribou Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caribou Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Moat Score falls into.


CRBU
64GF Score
Caribou Biosciences Inc CRBU
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Caribou Biosciences (CRBU) has a Moat Score of 5 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Caribou Biosciences ranks #46 out of 1395 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Caribou Biosciences' Moat Score too high?
Caribou Biosciences' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Caribou Biosciences' value of 5 is 150% above this industry median. Based on the distribution chart, Caribou Biosciences ranks #46 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Caribou Biosciences has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Moat Score compare to YDES and PRQR?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #46 out of 1395 companies for Moat Score. This places Caribou Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Caribou Biosciences' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caribou Biosciences's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.68, compared to a current price of $1.93 — trading 14.6% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Caribou Biosciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Moat Score is 5 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued. The current stock price of $1.93 is trading 14.6% above its estimated GF Value™ of $1.68. GuruFocus considers Caribou Biosciences to be Modestly Overvalued.

Key valuation signals for CRBU:

  • Moat Score: 5
  • GF Value™: $1.68 vs. price of $1.93 (14.6% above fair value)
  • GF Score™: 64/100 with 5 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1395)

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
64GF Score

Get the complete analysis for CRBU

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.68
GF Value